The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Open accessAbstract
Purpose: We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and Methods: A cycle of therapy consisted of bortezomib 1.3 mg/m 2 intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m 2 on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy. Twenty-three patients received a median of seven cycles of treatment. Results: Median bone marrow disease involvement declined from 55% to 10% (P = .0004), serum immunoglobulin M levels declined from 4,830 to 1,115 mg/dL (P < .0001), and hematocrit increased from 29.8% to 38.2% (P = .0002) at best response. The overall response rates and major response rates were 96% and 83% with three complete responses, two near complete responses, three very good partial responses, 11 partial responses, and three minor responses. Responses occurred at a median of 1.4 months. With a median follow-up of 22.8 months, 18 of 23 patients remained free of disease progression. Peripheral neuropathy was the most common toxicity, and it resolved to grade ≤ 1 in 13 of 16 patients at a median of 6.0 months. Four of the first seven treated patients developed herpes zoster, resulting in the institution of prophylactic antiviral therapy. Conclusion: The results demonstrate that BDR produces rapid and durable responses, along with high rates of response and complete remissions in WM. Herpes zoster prophylaxis is necessary with BDR, and reversible peripheral neuropathy was the most common toxicity leading to premature discontinuation of bortezomib in 61% of patients. Exploration of alternative schedules for bortezomib administration that includes weekly dosing should be pursued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Patients experiencing bortezomib-related PN had their dose reduced using guidelines previously established in patients with multiple myeloma.(33,34) Dose reduction of rituximab or dexamethasone was not permitted, but either drug could be held for toxicities as noted above.”
MethodSelf-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Owen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., San Miguel, J. F., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 924
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Self-citationRichardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Self-citationO'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Self-citationGoy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 472
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Chanan-Khan, A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9641 · Cited by 263
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Clinically relevant end points and new drug approvals for myeloma
Anderson, K. C., Kyle, R. A., Rajkumar, S. V., Stewart, A. K., Weber, D., Richardson, P., & Myeloma, O. B. O. T. A. /. P. O. C. E. I. M. (2008) · Leukemia · doi:10.1038/sj.leu.2405016 · Cited by 225
Ghobrial, I. M., Fonseca, R., Greipp, P. R., Blood, E., Rué, M., Vesole, D. H., & Gertz, M. A. (2004) · Cancer · doi:10.1002/cncr.20658 · Cited by 204
Self-citationGertz, M. A., Rué, M., Blood, E., Kaminer, L. S., Vesole, D. H., & Greipp, P. R. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001714043 · Cited by 198
Chen, C. I., Kouroukis, C. T., White, D., Voralia, M., Stadtmauer, E., Stewart, A. K., Wright, J. J., Powers, J., Walsh, W., & Eisenhauer, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8659 · Cited by 188
Strauss, S. J., Maharaj, L., Hoare, S., Johnson, P. W., Radford, J. A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6789 · Cited by 170
Self-citationLong-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Treon, S. P., Branagan, A. R., Ioakimidis, L., Soumerai, J. D., Patterson, C. J., Turnbull, B. A., Wasi, P., Emmanouilides, C. E., Frankel, S. R., Lister, A. T., et al. (2008) · Blood · doi:10.1182/blood-2008-09-177329 · Cited by 153
Self-citationThalidomide and rituximab in Waldenstrom macroglobulinemia
Treon, S. P., Soumerai, J. D., Branagan, A. R., Hunter, Z. R., Patterson, C. J., Ioakimidis, L., Briccetti, F., Pasmantier, M. W., Zimbler, H., Cooper, R. B., et al. (2008) · Blood · doi:10.1182/blood-2008-04-150854 · Cited by 142
Self-citationGlucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Treon, S. P., Soumerai, J. D., Branagan, A. R., Hunter, Z. R., Patterson, C. J., Ioakimidis, L., Chu, L., Musto, P., Baron, A. D., Nunnink, J. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0862 · Cited by 128
Self-citationTargeting NF-κB in Waldenstrom macroglobulinemia
Leleu, X. P., Eeckhoute, J., Jia, X., Roccaro, A. M., Moreau, A.-S., Farag, M., Sacco, A., Ngo, H. T., Runnels, J. M., Melhem, M. R., et al. (2008) · Blood · doi:10.1182/blood-2007-09-115170 · Cited by 109
Self-citationNiesvizky, R., Richardson, P. G. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07303.x · Cited by 102
Self-citationTreatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos, M. A., Anagnostopoulos, A. K., Kyrtsonis, M. C., Castritis, E., Bitsaktsis, A., & Pangalis, G. A. (2005) · PubMed · Cited by 99
Wang, M., Han, X., Zhang, L., Yang, J., Qian, J. F., Shi, Y., Kwak, L. W., Romaguera, J. E., & Yi, Q. (2007) · Leukemia · doi:10.1038/sj.leu.2404959 · Cited by 87
Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia
Roccaro, A. M., Leleu, X. P., Sacco, A., Jia, X., Melhem, M. R., Moreau, A., Ngo, H. T., Runnels, J. M., Azab, A., Azab, F., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120972 · Cited by 82
Self-citationIkezoe, T., Tanosaki, S., Krug, U. O., Liu, B.-R., Cohen, P., Taguchi, H., & Koeffler, H. P. (2004) · Blood · doi:10.1182/blood-2003-07-2203 · Cited by 69
Novel biologically based therapies for Waldenstrom's macroglobulinemia
Mitsiades, C. S., Mitsiades, N., Richardson, P. G. G., Treon, S. P., & Anderson, K. C. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50065 · Cited by 43
Self-citationGoekbuget, N., Baumann, A., Beck, J., Boos, J., Brüggemann, M., Diedrich, H., Hüttmann, A., Leimer, L., Lipp, T., Naumann, R., et al. (2008) · Blood · doi:10.1182/blood.v112.11.302.302 · Cited by 27
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
How I treat Waldenström macroglobulinemia
Treon, S. P. (2015) · Blood · doi:10.1182/blood-2015-01-553974 · Cited by 287
Self-citationLing, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043331 · Cited by 130
Metadata
- Authors
- Treon, S. P., Ioakimidis, L., Soumerai, J. D., Patterson, C. J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., Diener, J. G., Keogh, G. P., Myers, T. J., Boral, A., Birner, A., Esseltine, D. L., & Ghobrial, I. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3830-3835
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128490833
- Cited by
- 291
- References
- 33
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.